Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 6 sources · 26 days · First seen · Last updated
Pacira BioSciences corporate acquisitions
Overview
Pacira BioSciences has undergone significant structural changes through multiple acquisitions. In October 2026, Viatris entered a definitive agreement to acquire Pacira BioSciences in an all-cash transaction valued at approximately $1.65 billion. This acquisition aimed to incorporate Pacira’s non-opioid pain therapies, specifically Exparel and Zilretta, into the Viatris portfolio.
In November 2026, Zimmer Biomet agreed to acquire the Iovera business from Pacira BioSciences. The deal is valued at up to $140 million, consisting of a $70 million upfront payment and up to $70 million in revenue-based milestone payments through 2031. The Iovera system uses cold therapy to provide targeted, non-opioid pain relief for patients with knee pain or those undergoing joint replacement surgery. This acquisition is intended to strengthen Zimmer Biomet’s orthopaedics portfolio. The sale was intended to allow Pacira BioSciences to focus on its core biopharmaceutical business and its existing pipeline of non-opioid pain therapies.
Entities
Pacira BioSciences · Iovera · Scott Smith · Zimmer Biomet · Zilretta
Timeline
-
[BUSINESS] 6 sourcesZimmer Biomet to acquire Pacira BioSciences’ Iovera device
Zimmer Biomet is acquiring Pacira BioSciences’ Iovera device for up to $140 million while reporting Q3 2026 earnings that beat analyst revenue and profit expectations.
-
[BUSINESS] 3 sourcesViatris to acquire Pacira BioSciences for $1.65 billion
Viatris is acquiring Pacira BioSciences for $1.65 billion to add non-opioid pain therapies Exparel and Zilretta to its portfolio, aiming to provide alternatives to traditional opioid treatments.
Sources
ad-hoc-news.de · digitalhealth.london · finance.technews.tw · newsable.asianetnews.com · theascent.com · unilorin.edu.ng
This summary has been updated 1 time: see revision history